It focuses on creating long-term support routines that are compatible with high-functioning lifestyles - from professionals managing burnout risk to caregivers seeking energy regulation to parents trying to regain metabolic control without extreme diets or stimulant use
A spokesperson for Eli Lilly, which produces Zepbound and Mounjaro, told The Independent that Zepbound and Mounjaro autoinjectors and Zepbound vials are approved for single-use onlydose-splitting or microdosing is not contemplated by the FDA-label and may pose patient safety risks. Novo Nordisk, which produces Ozempic and Wegovy, told The Independent the company "[does] not condone the misuse of our products." The company noted it is concerned about non-FDA approved knock-off versions of semaglutide and sources spreading misinformation about GLP-1s to the public. The FDA warns that using unapproved versions of GLP-1 drugs can be risky for patients. This story was updated on September 4, 2025 to include responses from Eli Lilly and Novo Nordisk Join our commenting forum Join thought-provoking conversations, follow other Independent readers and see their replies Comments
Biologically active compounds like phospholipids can also increase the bioavailability or absorption of glutathione in your body
Treatment with acmopatide (CT-868), a dual glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor agonist (GLP-1/GIP RA), improved glycemic management while reducing weight, insulin dose, and blood pressure in a phase 2 clinical trial of adults living with type 1 diabetes and obesity
